Toboroz
Randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety of Roluperidone in adults with negative symptoms of schizophrenia
2026-525925-19-00· 3. fázis· Minerva Neurosciences Inc.· Forrás
Toboroz
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
NCT07686263· 3. fázis· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Forrás
Toboroz
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
NCT07424404· 3. fázis· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Forrás
Meghívásos bevonás
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
NCT07459660· 2. fázis· MapLight Therapeutics· Forrás
Toboroz
Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
NCT07288333· 2. fázis· Neurocrine Biosciences· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
NCT07288567· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
NCT07227454· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
NCT06887192· 2. fázis· MapLight Therapeutics· Forrás
Toboroz
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
NCT07105098· 3. fázis· Neurocrine Biosciences· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
NCT06929273· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A study to assess the efficacy and safety of ITI-1284 in the treatment of Psychosis Associated with Alzheimer's Disease
2024-513035-25-00· 2. fázis· Intra-Cellular Therapies Inc.· Forrás
Toboroz
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
NCT07114874· 3. fázis· Neurocrine Biosciences· Forrás
Toboroz
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
NCT07011732· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401· 3. fázis· Neurocrine Biosciences· Forrás
Toboroz
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
NCT06408259· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06911112· 3. fázis· Neurocrine Biosciences· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
NCT06651567· 2. fázis· Intra-Cellular Therapies, Inc.· Forrás
Toboroz
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787· 3. fázis· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
NCT06540833· 2. fázis· Intra-Cellular Therapies, Inc.· Forrás
Toboroz
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
NCT06559306· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949· 3. fázis· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Forrás
Toboroz
Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia
NCT05325645· 3. fázis· Otsuka Pharmaceutical Co., Ltd.· Forrás
Fut, nem toboroz
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
NCT05123703· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Clinical trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia. (EVOLUTION study)
2023-507372-42-00· 2. fázis· Oryzon Genomics S.A.· Forrás
Fut, nem toboroz
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
NCT01892722· 3. fázis· Novartis Pharmaceuticals· Forrás